Camber Announces Two New Product Launches
Camber Pharmaceuticals, one of the industry’s fastest growing generic pharmaceutical companies is pleased to announce the addition of two new products to its rapidly expanding product line.
The new products are as follows:
Benztropine Mesylate Finasteride
– .5mg / 100ct – 1mg/ 30ct and 90ct
– 1mg / 100ct and 1000ct
– 2mg / 100ct and 1000ct
Camber Pharmaceuticals is a fully integrated international pharmaceutical company that maintains quality and integrity in all its products from API manufacturing to finished dosage.
Camber’s parent company Hetero Drugs of Hyderabad, India employs over 300 scientists at 9 API facilities and has a global presence in over 100 countries.
Recent articles
- Camber Launches Eslicarbazepine Acetate Tablets
- Camber Launches Phenylephrine Hydrochloride Injection, USP
- Camber Launches Chlorzoxazone Tablets, USP
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year
- Camber Launches Lurasidone Hydrochloride Tablets
- Camber Launches Mycophenolate Mofetil Capsules